Deinove strengthens its position in the United States

By Deinove | February 25, 2015

Deinove, a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, recently announced that its patent, "High-performance metabolic bacteria,” has been granted in the United States. This patent covers the biofuel production process from cellulosic or hemicellulosic material—biomass components—by a consolidated bioprocess of degradation and fermentation based on Deinococcus bacteria. This issuance is a recognition of the innovative nature of the Deinol process in a leading country and participates in the proactive policy of protecting its intellectual property worldwide. Since its inception, Deinove has submitted more than 180 international patent applications divided into 17 families, leading to a highly valuable strategic asset.

This month, Deinve was admitted to the Biotechnology Industry Organization in the Industrial & Environmental section. As the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations, BIO advocates for its members, and works towards enriching the industry with networking, partnering and education opportunities. BIO organizes annual international conferences that have become references in the field.

The United States is a major market for Deinove. It is the world's largest ethanol producer with 51 billion liters (13.47 billion gallons) produced in 2013 against 40.7 billion liters in Brazil and only 6.7 billion liters in Europe . The major ethanol producers are located in the United States and are actively engaged in the development of second-generation ethanol production processes (2G). Over the past two years, at least eight 2G production units have opened up in the country with an annual capacity of more than 500 million liters.

Emmanuel Petiot, CEO of Deinove, said: "With this U.S. patent release, we confirm our competitive advantages and strengthen our ability to forge partnerships with US industry groups, as we did last year with the American derisking hub MBI. This patent supports the efforts we have undertaken in the United States and provides us with credibility. At the same time, our BIO membership will open up more opportunities for cooperation. We are confident in our technology development prospects in the world's largest market".